Retatrutide is a synthetic 39-amino acid peptide that acts on three receptors at once: GLP-1, GIP and glucagon. In the SOMA Research catalogue it is listed under the designation GLP-3 RT. This guide covers what the molecule is, how its triple-agonist mechanism differs from single- and dual-receptor peptides, how it is characterised analytically, and how to handle it in a laboratory setting. It is written for researchers evaluating the compound for in vitro and preclinical work.
SOMA Research supplies retatrutide for laboratory research use only. It is not a drug, supplement, food or cosmetic, is not approved by the FDA for any use, and is not intended for human or veterinary consumption.
What retatrutide is
Retatrutide is a peptide agonist built on a GIP-analogue backbone and modified to bind three distinct incretin and metabolic receptors. Its published identifiers are:
- CAS number: 2381089-83-2
- Molecular weight: approximately 4,731 g/mol
- Length: 39 amino acids
- Lipidation: a C20 diacid fatty-acid chain
- Catalogue designation: GLP-3 RT
The C20 diacid chain is the feature that governs its half-life. Fatty-acid acylation promotes reversible binding to serum albumin, which slows renal clearance and protects the peptide from enzymatic degradation. This is the same design principle used in other long-acting peptides, and it is why acylated peptides behave differently from their unmodified parent sequences in pharmacokinetic models.
Why it is called a triple agonist
Most incretin-targeting peptides engage one or two receptors. Retatrutide engages three:
- GLP-1 receptor — glucagon-like peptide-1 receptor, a class B G-protein-coupled receptor coupled primarily to Gs and cAMP signalling.
- GIP receptor — glucose-dependent insulinotropic polypeptide receptor, also class B GPCR, cAMP-coupled.
- Glucagon receptor (GCGR) — the third arm, and the one that distinguishes retatrutide from dual GIP/GLP-1 agonists such as tirzepatide.
The glucagon-receptor arm is mechanistically interesting because glucagon signalling has historically been considered opposed to GLP-1 signalling in glucose regulation. Adding controlled glucagon-receptor activity to an incretin agonist is a deliberate design choice studied for its effects on hepatic substrate handling and energy expenditure in preclinical models, rather than on insulin secretion alone.
How it compares to related research peptides
| Compound | Receptor targets | Class |
|---|---|---|
| Semaglutide | GLP-1 | Mono-agonist |
| Tirzepatide (GLP-2 TZ) | GIP + GLP-1 | Dual agonist |
| Retatrutide (GLP-3 RT) | GIP + GLP-1 + glucagon | Triple agonist |
For comparative receptor work, this progression is the useful framing: each step adds a signalling arm, so a three-compound panel lets a researcher attribute an observed effect to a specific receptor contribution rather than to incretin signalling in general.
Research context
Retatrutide was developed by Eli Lilly and has been the subject of published clinical investigation under the code LY3437943. Those trials are the developer’s own clinical programme and concern a pharmaceutical product; they are cited here only as the published literature on the molecule. Research-grade retatrutide supplied for laboratory use is not that product, is not manufactured to pharmaceutical standards, and must not be used in or on humans or animals.
Published preclinical literature on the compound centres on receptor binding and selectivity profiling, cAMP accumulation assays across the three receptor types, and metabolic phenotyping in rodent models. For a researcher designing in vitro work, the receptor-potency ratios reported across GLP-1R, GIPR and GCGR are the primary parameters of interest, since they determine the concentration range at which each arm contributes measurably.
Purity and identity: what to require
Retatrutide is a long peptide with a lipid modification, which makes it harder to synthesise cleanly than a short unmodified sequence. Two analytical results matter:
HPLC for purity
High-Performance Liquid Chromatography separates the sample and reports the target peptide as a percentage of total peak area. For a 39-residue acylated peptide, the realistic failure modes are deletion sequences (a residue missed during synthesis), truncated chains, and incompletely acylated material. These co-elute closely with the target, so chromatographic resolution matters as much as the headline number.
Mass spectrometry for identity
HPLC purity alone cannot tell you the peak is the right molecule. Mass spectrometry confirms the observed mass matches the theoretical mass for the intended sequence and modification. A compound reported at high HPLC purity with no mass confirmation is pure something — which is not the same claim.
SOMA publishes both for every batch. The current retatrutide lots are documented on the Certificates of Analysis page, and the method behind those documents is described in How to Read a Certificate of Analysis. Batch-level reporting is the point: a CoA describes one production run, not a product line.
Handling and stability
Acylated peptides are sensitive to the same things all peptides are, plus a tendency to aggregate at the air-water interface because of the lipid chain.
- Lyophilised powder: stable at −20°C for 24+ months when kept dry and protected from light.
- Reconstituted solution: approximately 30 days at 2–8°C.
- Freeze-thaw: avoid repeated cycles. Aliquot after reconstitution rather than refreezing the stock.
- Light: protect from light at all stages.
- Agitation: swirl or roll to dissolve. Vortexing drives foaming, and foam is an aggregation interface.
Allow a vial to reach room temperature before opening it. Introducing diluent into a cold vial pulls moisture from the air onto the powder, and a lyophilised peptide is hygroscopic.
Verifying what you received
Three checks on arrival, in order:
- Match the lot number on the vial to the lot number on the CoA. A CoA for a different lot documents different material.
- Confirm both assays are present on that CoA — HPLC and MS, not one of the two.
- Check the testing laboratory is independent of the supplier. In-house results are not worthless, but they are not third-party verification, and only one of those two is a check on the seller.
Frequently asked questions
What is retatrutide?
Retatrutide is a synthetic 39-amino acid peptide that acts as an agonist at three receptors — GLP-1, GIP and glucagon. It carries a C20 diacid fatty-acid chain and has CAS number 2381089-83-2. SOMA Research lists it under the catalogue designation GLP-3 RT and supplies it for laboratory research use only.
What is the difference between retatrutide and tirzepatide?
Tirzepatide is a dual agonist at the GIP and GLP-1 receptors. Retatrutide adds a third arm, the glucagon receptor. That extra receptor is the structural and mechanistic difference between the two compounds.
Why does SOMA list retatrutide as GLP-3 RT?
GLP-3 RT is an internal catalogue designation used on product labelling and in the shop. It refers to the same compound, retatrutide, CAS 2381089-83-2, and each product page states the CAS number and molecular weight so the identity is unambiguous.
How should research-grade retatrutide be stored?
Store the lyophilised powder at −20°C protected from light, where it is stable for 24 months or more. Once reconstituted, keep it at 2–8°C and use within about 30 days. Avoid repeated freeze-thaw cycles by aliquoting the reconstituted stock.
Is research-grade retatrutide the same as the pharmaceutical product?
No. Research-grade peptide is supplied for laboratory use, is not manufactured to pharmaceutical standards, has not been approved by the FDA for any use, and is not for human or veterinary consumption.
Related guides
- HPLC vs mass spectrometry: why a CoA needs both
- Peptide storage and stability
- How to reconstitute a research peptide
- Retatrutide vs tirzepatide compared
SOMA Research products are intended for laboratory and research use only. They are not drugs, foods, cosmetics, or supplements, are not intended to diagnose, treat, cure, or prevent any disease or condition, and are not for human or animal consumption. Nothing on this page is medical advice.
